These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 34694009)

  • 1. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
    Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.
    Wetwittayakhlang P; Albader F; Golovics PA; Hahn GD; Bessissow T; Bitton A; Afif W; Wild G; Lakatos PL
    Can J Gastroenterol Hepatol; 2021; 2021():7591141. PubMed ID: 34858891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
    Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC
    Front Immunol; 2022; 13():920333. PubMed ID: 35865529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
    Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
    Lin S; Lau LH; Chanchlani N; Kennedy NA; Ng SC
    Gut; 2022 Jul; 71(7):1426-1439. PubMed ID: 35477864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease.
    Stercel V; Lóczi L; Kadenczki O; Nemes É; Nagy B; Hodossy-Takács R; Szabó AÁ; Fagyas M; Kappelmayer J; Szabó T; Bagoly Z
    Front Immunol; 2023; 14():1257072. PubMed ID: 37965328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 in IBD: The experience of a single tertiary IBD center.
    Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
    Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
    Brenner EJ; Pigneur B; Focht G; Zhang X; Ungaro RC; Colombel JF; Turner D; Kappelman MD; Ruemmele FM
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):394-396.e5. PubMed ID: 33059040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
    Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ
    Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.
    Chen L; Hu K; Cheng C; Hu Q; Zhang L; An T; Guo Y; Chen S; Duan G
    Int J Colorectal Dis; 2022 Nov; 37(11):2277-2289. PubMed ID: 36271206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Disease Phenotype and Course among Elderly- and Early-Onset Inflammatory Bowel Diseases in the Middle East.
    Vosoghinia H; Saberzadeh-Ardestani B; Anushiravani A; Mansour-Ghanaei F; Fakheri H; Vahedi H; Sheikhesmaeili F; Yazdanbod A; Moosavy SH; Maleki I; Nasseri-Moghaddam S; Khosravi B; Malekzadeh M; Kasaeian A; Alatab S; Sadeghi A; Kolahdoozan S; Amani M; Saberhosseini SN; Rayatpisheh M; Ahadi M; Colombel JF; Ungaro RC; Sima AR; Malekzadeh R
    Arch Iran Med; 2023 Sep; 26(9):481-488. PubMed ID: 38310403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
    Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
    Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
    Burke KE; Kochar B; Allegretti JR; Winter RW; Lochhead P; Khalili H; Colizzo FP; Hamilton MJ; Chan WW; Ananthakrishnan AN
    Inflamm Bowel Dis; 2021 Jan; 27(2):155-161. PubMed ID: 33089863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study.
    Zhang M; Huang Q; Shi C; Feng Y; Duan T; Lin T; Zhu Y; Liu G; Li H; Liu Y; Jiang B
    Int J Colorectal Dis; 2023 Feb; 38(1):31. PubMed ID: 36757427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of pneumonia among patients with inflammatory bowel disease.
    Long MD; Martin C; Sandler RS; Kappelman MD
    Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark.
    Burisch J; Jess T; Egeberg A
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2704-2712.e3. PubMed ID: 30936024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
    Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
    Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.
    Esposito S; Caminiti C; Giordano R; Argentiero A; Ramundo G; Principi N
    Front Immunol; 2022; 13():933774. PubMed ID: 35812420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.